机构:[1]Beijing Institute of Ophthalmology, Beijing Tongren Eye Center, Beijing Tongren Hospital, Capital Medical University, Beijing Ophthalmology and Visual Sciences Key Laboratory, Beijing 100730, P.R. China.研究所眼科研究所首都医科大学附属北京同仁医院首都医科大学附属同仁医院[2]Department of Ophthalmology, Chinese PLA General Hospital, Beijing 100853, P.R. China.
Following the publication of this paper, it was drawn to the Editors' attention by a concerned reader that three data panels featured in the flow cytometric plots shown in Figs. 5D and 6D, and several panels from the cell invasion assays shown in Figs. 5C and 6C, were strikingly similar to data appearing in different form in other articles by different authors. Owing to the fact that the contentious data in the above article were already under consideration for publication prior to its submission to Oncology Reports, the Editor has decided that this paper should be retracted from the Journal. After having been in contact with the authors, they agreed with the decision to retract the paper. The Editor apologizes to the readership for any inconvenience caused. [Oncology Reports 39: 2402‑2412, 2018; DOI: 10.3892/or.2018.6302].
语种:
外文
PubmedID:
中科院(CAS)分区:
出版当年[2021]版:
大类|3 区医学
小类|3 区肿瘤学
最新[2025]版:
大类|3 区医学
小类|4 区肿瘤学
第一作者:
第一作者机构:[1]Beijing Institute of Ophthalmology, Beijing Tongren Eye Center, Beijing Tongren Hospital, Capital Medical University, Beijing Ophthalmology and Visual Sciences Key Laboratory, Beijing 100730, P.R. China.
推荐引用方式(GB/T 7714):
Wu Shen,Ai Nanping,Liu Qian,et al.[Retracted] MicroRNA‑448 inhibits the progression of retinoblastoma by directly targeting ROCK1 and regulating PI3K/AKT signalling pathway.[J].Oncology Reports.2022,48(2):doi:10.3892/or.2022.8351.
APA:
Wu Shen,Ai Nanping,Liu Qian&Zhang Jingxue.(2022).[Retracted] MicroRNA‑448 inhibits the progression of retinoblastoma by directly targeting ROCK1 and regulating PI3K/AKT signalling pathway..Oncology Reports,48,(2)
MLA:
Wu Shen,et al."[Retracted] MicroRNA‑448 inhibits the progression of retinoblastoma by directly targeting ROCK1 and regulating PI3K/AKT signalling pathway.".Oncology Reports 48..2(2022)